EVC
GILD icon

Eidelman Virant Capital’s Gilead Sciences GILD Stock Holding History

Eidelman Virant Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,800
Closed -$211K – 150
2015
Q2 		$211K Buy
+1,800
New +$197K 0.09% 136
2014
Q4 		– Sell
-2,800
Closed -$298K – 183
2014
Q3 		$298K Sell
2,800
-200
-7% -$19.6K 0.14% 113
2014
Q2 		$249K Sell
3,000
-3,000
-50% -$234K 0.1% 136
2014
Q1 		$425K Buy
+6,000
New +$471K 0.2% 92
2013
Q3 		– Sell
-16,900
Closed -$866K – 160
2013
Q2 		$866K Buy
+16,900
New +$881K 0.51% 57

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Eidelman Virant Capital's GILD Position: Q3 2015 in Review

Eidelman Virant Capital sold out of Gilead Sciences (GILD) in Q3 2015, closing a stake of 1,800 shares — an estimated $211K sold.

Eidelman Virant Capital first reported a position in GILD in Q2 2013 and held it in 5 quarters. The position peaked at $866K in Q2 2013. 1,572 funds tracked by Wall St. Rank hold GILD as of Q3 2015.

  • Eidelman Virant Capital reported no remaining Gilead Sciences position as of Q3 2015 after selling out during the quarter.
  • Eidelman Virant Capital sold 1,800 Gilead Sciences shares in Q3 2015, an estimated $211K.
  • Eidelman Virant Capital first reported a position in Gilead Sciences in Q2 2013 and held it in 5 quarters.
  • Eidelman Virant Capital's Gilead Sciences position peaked at $866K in Q2 2013.
  • 1,572 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2015.

Based on Eidelman Virant Capital's 13F filing for Q3 2015, filed 30 Oct 2015.